UroGen Pharma Ltd’s market performance has been unstable in recent times. The company’s stock hit a 1-year high of $20.70 on 06/14/24 and a low of $10.54 for the same time frame on 12/20/24.
52-week price history of URGN Stock
A stock’s 52-week high and low prices can reveal much about its current status and future trajectory. UroGen Pharma Ltd’s current trading price is -48.12% away from its 52-week high, while its distance from the 52-week low is 1.90%. The stock’s price range during this period has spanned from $10.54 to $20.70. In the Healthcare sector, the UroGen Pharma Ltd’s shares surpassed a trading volume of approximately 0.94 million for the day, which was noticeably higher compared to the average daily volume of 9.0.53 million over the past three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Market Capitalization and Financial Performance: An In-Depth Look
UroGen Pharma Ltd (URGN) has experienced a quarterly decline of -17.19% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 453.23M and boasts a workforce of 201 employees.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 12.91, with a change in price of -5.78. Similarly, UroGen Pharma Ltd recorded 525,157 in trading volume during the last 100 days, posting a change of -35.14%.
Examining URGN’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for URGN stands at 4.81. Similarly, the long-term debt-to-equity ratio is also 4.78.
URGN Stock Stochastic Average
Today, UroGen Pharma Ltd’s raw stochastic average for the past 50 days stands at 4.19%, indicating a decline from the raw stochastic average of the last 20 days, which was 5.01%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 6.23% and 11.99% respectively.
URGN Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. Until today this year the stock’s price performance recorded a decrease of -28.40%. However, over the last six months, the performance has been stronger by -38.52%. The price of URGN decreased -6.20% over the last 30 days. And in the last five days, it has fallen by -5.37%.
